Slide 1: Assertio Therapeutics and Zyla Life Sciences Agree to Merge
Assertio Therapeutics and Zyla Life Sciences Agree to Merge A Specialty Pharmaceutical Company Driving Growth through Commercial Excellence and Business Development March 17, 2020
Slide 2: Forward Looking Statement
2 | Forward Looking Statement Statements in this communication that are not historical facts are forward - looking statements that reflect Assertio’s and Zyla’s respective management’s current expectations, assumptions and estimates of future performance and economic conditions. These forward - look
Slide 3: No Offer or Solicitation
3 | No Offer or Solicitation This communication relates to a proposed business combination involving Assertio and Zyla. The information in this communicat ion is for informational purposes only and is neither an offer to purchase, nor a solicitation of an offer to sell, subscribe for or buy any secu
Slide 4: A Transformational Combination Driving Growth through Commercial Excellence and Business Development
4 | A Transformational Combination Driving Growth through Commercial Excellence and Business Development New Holding Company to Have a Leading Portfolio of Branded NSAIDs in the United States • One - stop shop for opioid alternatives • Important for patients and HCPs to have options when many are be
Slide 5: Combined Company Highlights
5 | Combined Company Highlights Deal Terms and Closing • Zyla shareholders will be entitled to 2.5 shares of common stock of holding company for each share of Zyla common stock held • Newly formed holding company will retain the Assertio name • Expected to close in the second quarter Portfolio and S
Slide 6: Synergies Will Create Robust Value
6 | Synergies Will Create Robust Value Continued Focus on Operational Efficiency Reduction in Total Debt Upwards of $40 Million Continued Opportunities for Synergies SG&A • Commercial efficiencies • Duplicative overhead • Support functions and technology systems Operations • Supply chain optimizatio
Slide 7: Combination Creates Sustainable Growth
7 | Combination Creates Sustainable Growth Provides complementary diversification Potential to unlock shareholder value Reduction in Total Debt Existing Portfolio Expected to Grow High Single Digits Reduction in Total Debt Ability to Accelerate Growth Through Smart Acquisitions Reduction in Total De
Slide 8: A Leading Branded NSAID Portfolio
8 | A Leading Branded NSAID Portfolio Three Strategic Business Units Focused Across Multiple Therapeutic Areas Traditional NSAID Targets Ortho, Women’s Health, Podiatry, Urology Neurology Headache Hospital Inflammation and Pain
Slide 9: The Proven Power of Platform: SPRIX Nasal Spray
9 | 2015 Acquired underpromoted SPRIX in January 2015 and built commercial salesforce Launched commercial promotion of SPRIX in June 2015 Demonstrated commercial excellence with continued growth 2015 - 2018 Indicated in adult patients for the short term (up to 5 days) management of moderate to moder
Slide 10: Indocin Positioned to Grow
10 | Indocin Positioned to Grow The Only NSAID Available in the U.S. in a Suppository Form • The Indomethacin segment is large with over 2MM TRx annually , nearly exclusively in capsule formulation • Indocin represents a fraction of the segment (Indocin OS = 0.1%, Indocin Suppository = 0.04%) of thi
Slide 11: Driving Total Prescription Growth: Cambia
11 | Driving Total Prescription Growth Significant Improvement and Execution for Cambia Only FDA - approved single - agent prescription NSAID that provides rapid onset of action and proven efficacy Total prescription data is based on Symphony prescriber level data. This includes estimates, which cou
Slide 12: Zipsor and Zorvolex
12 | Zipsor and Zorvolex Rapid non - opioid relief via unique ProSorb Dispersion Technology that results in peak plasma levels in 27 minutes Total prescription data is based on Symphony prescriber level data. This includes estimates, which could cause minor fluctuations in historical comparisons. Al
Slide 13: Leadership of the combined company
13 | ▪ Joined in March 2017 and brings over 35 years of pharmaceutical and healthcare industry experience ▪ Previously served as Chairman of Bayer HealthCare and helped transform the company into a global leader in global pharmaceutical and consumer healthcare ▪ Former Chairman, President and Chief
Slide 14: Transaction Next Steps
14 | Transaction Next Steps Announce the deal and file merger agreement. Subject to customary review and closing requirements. Obtain shareholder approvals . Expected to close in the second quarter. Shares to be traded under Assertio Therapeutics (ASRT) on the Nasdaq. x Announce Review Close Working
Slide 15: Supplemental Information
Supplemental Information
Slide 16: Assertio Therapeutics Overview
16 | Assertio Therapeutics Overview A Leading Specialty Pharmaceutical Company • Focus: Specialty pharmaceutical company focused on non - opioids and neurology, contemplating growth in rare disease space • Products: Cambia and Zipsor, both growing NSAIDs • Headcount: 125, including 72 sales represen
Slide 17: Zyla Life Sciences Overview
17 | Zyla Life Sciences Overview A Leading Commercial Company • Focus: Specialty pharmaceutical company focused on delivering differentiated products to doctors in a range of specialties including neurology, orthopedic surgery, women’s health, podiatry, physiatry and internal medicine • Products: Si